Archive | April, 2020

RESI’s New Global Partnering Event – Breaking Down Barriers

30 Apr

By Gregory Mannix, Chief Conference Officer, Vice President International Business Development, LSN

The metrics and the global reach of the first Digital RESI 2-Day Partnering Event happening this week has shown that business development and investment in the life sciences can and must go on, despite the challenges of not being able to travel to major event venues as we have all done in the recent past. The response to this new format in these new and challenging times has been immense. The numbers speak for themselves.

  •          500 Participating Attendees
  •          1,450 Virtual Partnering Meetings
  •          Participants from 5 Continents
  •          48 hours of uninterrupted partnering

1,450 Partnering Meetings

Life Science Verticals Participating

Investors and Strategic Partners

Investor Types Participating

 

 

Partnering Activity

April 29th, 2020, at 7:00 a.m. Est

April 29th, 2020, at 10:00 a.m. Est

April 29th, 2020, at 1:00 p.m. Est

April 29th, 2020, at 4:00 p.m. Est

April 29th, 2020, at 11:00 p.m. Est

April 30th, 2020, at 3:00 a.m. Est

 

Digital RESI June: Across 4 Continents, Fundraising CEOs and Investors, 24/7 Access, June 8th thru 10th

30 Apr

By Claire Jeong, Vice President of Investor Research, Asia BD, LSN

claireDigital RESI June is fast approaching, and, once again, there is an exciting panel lineup featuring investors and strategic partners sharing their insights with startup attendees. The panels will include ever popular panels such as Big Pharma, Corporate Venture Capital, and Family Offices and Angels. Other panels will cover specific topics such as Mental and Behavioral Health, AI in Healthcare and our newest panel, Longevity and Age-Related Disease. Also available will be workshops for startups, giving advice on legal issues, valuation and how to run a fundraising campaign. These panels will be prerecorded and posted on the Digital RESI Agenda page, along with all of the other RESI content, including the RESI Innovation Challenge participants, the Featured Company Pitch participants, and a virtual Exhibit Hall for exhibitors. The digital format of the conference is allowing us to include even more panels than at an on-site event, without taking away from partnering meetings to take advantage of the panel content. Check out all of the panels below, and keep an eye out for speaker spotlights!

Fundraising CEOs: Reserve Your Spot in the “Featured Company Pitch Session” For June Digital RESI

30 Apr

By Karen Deyo, Senior Investor Research Analyst, LSN

LSN is giving startups an opportunity to pitch and have a live Q&A session with a panel of investors during the upcoming Digital RESI in June. Each company will have a 4-minute prerecorded pitch posted on a dedicated page linked from the Digital RESI Live Agenda, increasing their exposure to the 350+ investor attendees. In addition, companies will participate in a live Q&A session with a panel of relevant investors. Interested in pitching? Fill out the following application and send your pitch deck and executive summary to resi@lifesciencenation.com. Companies are selected on a rolling basis, so make sure to get your application in soon!

SPECIAL OFFER: Companies that apply to pitch and register June 3-day Digital RESI conference before May 8th will have the webpage fee of $250 waived, and enjoy the discounted price of $500.

Hot Investor Mandate: Cross Border Firm with USD and RMD Denominated Funds Invests Up to $10M in Technologies that Target Oncology, Infectious Disease, Autoimmune Disorders

30 Apr

A healthcare-focused venture investment fund with a team who are all trained in biomedical fields, with healthcare industry experience and years of successful investment or entrepreneurship experience in China, has past investment portfolio companies cover areas such as drug, device, diagnostics, healthcare IT and medical services. These investments were over $10MM and were made in venture rounds from Series A-C. The firm currently manages both RMB and US Dollar funds, investing in early and growth-stage companies in China and overseas. The firm believes in the huge industry growth and significant investment opportunities in China healthcare space for the next 10 to 20 years.

The firm has invested in therapeutics in a wide range of indications, including cancer, infectious diseases and autoimmune disorders. These investments covered a wide range of modalities including small molecules, antibodies and gene therapies. The firm additionally invested in medical device and imaging technologies, such as ultrasound and cardiovascular devices. Therapeutic investments were made during pre-clinical trials, while device investments were made pre-market. The firm invested in bioinformatics, research tools and animal medicine as well. The firm has invested in companies in the US, China and Western Europe.

The firm has no specific management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA Investment Firm Seeks Early-Stage Technologies that Intersect Biology, Technology, and Data Science

30 Apr

A venture capital firm based in the USA invests in companies dedicated to working on the intersection of biology, technology, and data science. The firm is focused on early-stage investments from Seed to Series A and also dedicates funds to follow-on investment. Initial check sizes are usually between $1-2M but can fall outside of this range on a case-by-case basis. The firm will consider global opportunities.

The firm invests in the intersection of biology, technology, and data science and the areas of interest fall beyond traditional sectors. The firm is focused on (1) technology driving biology (miniaturization, automation, data sciences); (2) biology as technology (synthetic biology, genetic engineering, stem cells); (3) biology beyond healthcare (agriculture, chemicals/industrials, consumer). The firm will consider cutting edge therapeutics/drug development and platform technologies and diagnostics, is not interested in traditional medical devices or digital health.

The firm focuses on privately owned, early stage companies and is open to working with all types of management teams. The firm likes to step in early and prefers to act as the lead investor, but is open to co-investing as well.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: China Headquartered VC Firm Invests Up to $6M in Early-Stage Life Science Technologies in North America, Most Interested in Personalized Medicine Products

30 Apr

A venture capital firm with China headquarters and additional USA office is investing from its US$200 million fund with a focus on high-tech enterprises in China and Western countries. The firmseeks to invest in innovative enterprises in sectors including: biomedicine, medical devices, healthcare and bio-tech. Typical equity investments range from $1-6 million in Angel, Series A and B rounds. The firm is looking for opportunities in China, the US and Canada.

Within healthcare, the firm considers biomedicine, medical devices, and healthcare IT. The firm is most interested in personalized medicine products with an angle to the China market. Within healthcare IT, the firm prefers home-care, consumer, or physician-patient interface products. The firm considers products from Angel Round to Series B.

The firm is looking for competent management teams. The firm may request distribution rights on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: East Coast USA-Based Family Office Seeks Medical Devices & Diagnostics Investments, as well as First Class Therapeutics and AI

30 Apr

A family office based in East Coast USA looks to invest in medical devices and diagnostics, but will also consider therapeutics and digital health. The firm prefers company that have some proof of concept data, with some animal studies complete, and will invest through to clinical-stage companies. The firm generally co-invests in a syndicate, and will invest between $100-500K, depending on the stage of development of the company. The firm is currently interested in investing in companies located in North America.

The firm is focused primarily on medical devices and diagnostics, but will consider therapeutics, if they are first in class, and digital health, with a focus on AI-related technologies. The firm has focused on technologies related to oncology, diabetes and kidney diseases, but will consider other indications as well.

The firm is interested in companies with strong management teams. As the firm will generally co-invest, board representation is not usually required after investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries